223
Participants
Start Date
November 21, 2016
Primary Completion Date
February 27, 2020
Study Completion Date
August 31, 2026
LY3200882
Administered orally
LY3300054
Administered intravenously
Gemcitabine
Administered intravenously
nab-Paclitaxel
Administered intravenously
Cisplatin
Administered intravenously
Intensity Modulated Radiotherapy
St Vincent's Hospital Sydney, Sydney
Calvary Mater Newcastle, Newcastle
Greenslopes Private Hospital, Greenslopes
Weill Cornell Medical College, New York
Charité Campus Virchow-Klinikum, Berlin
Istituto Clinico Humanitas, Rozzano
Hospital Universitario 12 de Octubre, Madrid
Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona
University of Louisville, Louisville
Hospital Clínico Universitario de Valencia, Valencia
CHRU de Lille, Lille
Hopital Saint-Louis, Paris
University of Texas MD Anderson Cancer Center, Houston
Gustave Roussy, Villejuif
Universitätsklinikum Würzburg A. ö. R., Würzburg
Princess Margaret Hospital (Ontario), Lai Chi Kok
National Cancer Center Hospital, Chuo-Ku
Hospital Universitari Vall d'Hebron, Barcelona
Eli Lilly and Company
INDUSTRY